Glaxosmithkline Plc Adr Stock Performance
| GSK Stock | USD 40.88 0.36 0.87% |
GlaxoSmithKline PLC has a performance score of 9 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.58, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, GlaxoSmithKline PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding GlaxoSmithKline PLC is expected to be smaller as well. GlaxoSmithKline PLC ADR right now retains a risk of 0.99%. Please check out GlaxoSmithKline PLC coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if GlaxoSmithKline PLC will be following its current trending patterns.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in GlaxoSmithKline PLC ADR are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain basic indicators, GlaxoSmithKline PLC may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return (1.04) | Five Day Return 3.66 | Year To Date Return 8.8 | Ten Year Return (26.48) | All Time Return 8.3 K |
Forward Dividend Yield 0.0356 | Payout Ratio 0.3756 | Last Split Factor 1226:1000 | Forward Dividend Rate 1.47 | Dividend Date 2024-04-11 |
1 | Clinical Trial Supplies market is projected to grow at a CAGR of 8.8 percent by 2034 Visiongain | 03/18/2024 |
2 | Projected Surge in Indolent Lymphoma Market by 2032, estimates DelveInsight | 03/25/2024 |
3 | Improving Contract Literacy Praktio Launches On-demand Course for Marmons Business Professionals | 04/02/2024 |
4 | GSK, Pfizer-backed ViiV gets FDA okay for HIV drug for adolescents | 04/08/2024 |
5 | Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of 6 percent by 2030, Assesses DelveInsight | 04/09/2024 |
6 | Global Dietary Supplements Market to Grow Immensely by 2030, Predicts DelveInsight Key Companies - Amway, Abbott, Bayer, Pfizer, Otsuka, GlaxoSmithKline, Americ... | 04/10/2024 |
| GlaxoSmithKline PLC dividend paid on 11th of April 2024 | 04/11/2024 |
8 | Global Retinoid Market Poised for Growth, Expected to Reach US 3.05 Billion by 2034 at a moderate CAGR of 6.5 percent Future Market Insights | 04/15/2024 |
9 | Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer | 04/17/2024 |
10 | 23andMe CEO plans to take company private | 04/18/2024 |
11 | Chobani Australia Welcomes Scott Hadley as Managing Director | 04/22/2024 |
12 | Takeda Pharmaceutical A Long-Term Cash Cow | 04/23/2024 |
| Begin Period Cash Flow | 3.7 B | |
| Total Cashflows From Investing Activities | -1.6 B |
GlaxoSmithKline |
GlaxoSmithKline PLC Relative Risk vs. Return Landscape
If you would invest 3,846 in GlaxoSmithKline PLC ADR on January 25, 2024 and sell it today you would earn a total of 278.00 from holding GlaxoSmithKline PLC ADR or generate 7.23% return on investment over 90 days. GlaxoSmithKline PLC ADR is generating 0.1156% of daily returns assuming volatility of 0.9902% on return distribution over 90 days investment horizon. In other words, 8% of stocks are less volatile than GlaxoSmithKline, and above 98% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
GlaxoSmithKline PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GlaxoSmithKline PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GlaxoSmithKline PLC ADR, and traders can use it to determine the average amount a GlaxoSmithKline PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1168
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | GSK | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 0.99 actual daily | 8 92% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average GlaxoSmithKline PLC is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GlaxoSmithKline PLC by adding it to a well-diversified portfolio.
GlaxoSmithKline PLC Fundamentals Growth
GlaxoSmithKline Stock prices reflect investors' perceptions of the future prospects and financial health of GlaxoSmithKline PLC, and GlaxoSmithKline PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlaxoSmithKline Stock performance.
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.0881 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 179.06 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 4.96 X | ||||
| Price To Sales | 2.75 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 9.29 B | ||||
| Net Income | 4.93 B | ||||
| Cash And Equivalents | 3.72 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 18.02 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 3.29 X | ||||
| Cash Flow From Operations | 6.35 B | ||||
| Earnings Per Share | 2.97 X | ||||
| Market Capitalization | 84.25 B | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.24 B | ||||
| Working Capital | (2.42 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
About GlaxoSmithKline PLC Performance
To evaluate GlaxoSmithKline PLC ADR Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when GlaxoSmithKline PLC generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare GlaxoSmithKline Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand GlaxoSmithKline PLC ADR market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents GlaxoSmithKline's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 221.11 | 153.41 | |
| Return On Tangible Assets | 0.13 | 0.21 | |
| Return On Capital Employed | 0.18 | 0.18 | |
| Return On Assets | 0.08 | 0.15 | |
| Return On Equity | 0.37 | 0.42 |
Things to note about GlaxoSmithKline PLC ADR performance evaluation
Checking the ongoing alerts about GlaxoSmithKline PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlaxoSmithKline PLC ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| On 11th of April 2024 GlaxoSmithKline PLC paid $ 0.4061 per share dividend to its current shareholders | |
| Latest headline from gurufocus.com: Takeda Pharmaceutical A Long-Term Cash Cow |
- Analyzing GlaxoSmithKline PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlaxoSmithKline PLC's stock is overvalued or undervalued compared to its peers.
- Examining GlaxoSmithKline PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlaxoSmithKline PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlaxoSmithKline PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlaxoSmithKline PLC's stock. These opinions can provide insight into GlaxoSmithKline PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Dividend Share 0.58 | Earnings Share 2.97 | Revenue Per Share 14.97 | Quarterly Revenue Growth 0.092 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.